Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01800968 · ClinicalTrials.gov registry record · Phase 2
Functional Impact of GLP-1 for Heart Failure Treatment (FIGHT)
A Phase 2 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 2
- Development phase
- 300
- Enrollment target
NCT01800968 is a Phase 2 study that has completed, run by Duke University. The registered enrollment target is 300 participants.
The verdict
NCT01800968, a Phase 2 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 300 participants
- Enrollment target
Study Summary
The primary objective is to test the hypothesis that, compared with placebo, therapy with Subcutaneous (SQ) GLP-1 agonist in the post-Acute Heart Failure Syndrome (AHFS) discharge period will be associated with greater clinical stability at six months as assessed by a composite clinical endpoint.
Interventions
- DRUG Placebo
- DRUG Liraglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2013-04 |
| Est. Completion | 2015-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01800968
The ClinicalTrials.gov registry entry for NCT01800968 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01800968 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01800968 about?
NCT01800968 is a clinical study titled "Functional Impact of GLP-1 for Heart Failure Treatment (FIGHT)". The primary objective is to test the hypothesis that, compared with placebo, therapy with Subcutaneous (SQ) GLP-1 agonist in the post-Acute Heart Failure Syndrome (AHFS) discharge period will be associated with greater clinical stability at six months as assessed by a composite clinical endpoint.
What is the current status of trial NCT01800968?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2013-04. Estimated completion is 2015-10.
What interventions are being tested in trial NCT01800968?
The interventions under investigation include: Placebo (DRUG), Liraglutide (DRUG).
Who is sponsoring clinical trial NCT01800968?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.